tirzepatide and increased heart rate Can cause a 10‑bpm increase in resting in a patient titrated from 2.5 mg weekly subcutaneous dosing? The Cardiovascular Effect of Tirzepatide:

Weight regain and appetite rebound are well-documented

For the cardiovascular risk reduction indication, some Medicare Advantage plans may cover Wegovy following the 2024 CMS guidance

If your blood sugar drops too low, it can lead to fatigue

Curb cravings

The diabetes-versus-obesity nuance It is worth noting that in the REDEFINE 2 study of CagriSema in people with type 2 diabetes, the weight-loss magnitude was somewhat lower than in the non-diabetes REDEFINE 1 population a reminder that efficacy (and by extension any downstream liver benefit) is population-dependent, and that MASH patients, who frequently have diabetes, may respond differently than the leaner-metabolism trial populations

(verified owner) Verified review - view original So far so good